Celgene To Buy Juno Therapeutics For Approximately $87 Per Share In Cash
January 22, 2018 at 09:23 AM EST
Celgene Corporation and Juno Therapeutics announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.